The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors

Leukemia

Volumn 25, Issue 2, 2011, Pages 321-330

  De Boer, J ^a   Yeung, J ^a   Ellu, J ^a   Ramanujachar, R ^a   Bornhauser, B ^b   Solarska, O ^a   Hubank, M ^a   Williams, O ^a   Brady, H J M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

B precursor ALL; Bcl 2; E2A HLF; Lmo2; t(17; 19)

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DOXORUBICIN; E2A HLF PROTEIN; HYBRID PROTEIN; LMO2 PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR E2A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL IMMORTALIZATION; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG SENSITIZATION; FETUS; GENE SILENCING; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHOID CELL LINE; LYMPHOID PROGENITOR CELL; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 79751529186     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.253     Document Type: Article

References (39)

1. Raimondi SC, Privitera E, Williams DL, Look AT, Behm F, Rivera GK et al. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood 1991; 77: 2016-2022.
2. Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531-534.
3. Hunger SP, Ohyashiki K, Toyama K, Cleary ML. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 1992; 6: 1608-1620.
4. Hunger SP, Brown R, Cleary ML. DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF. Mol Cell Biol 1994; 14: 5986-5996. (Pubitemid 24264427)
5. Inaba T, Shapiro LH, Funabiki T, Sinclair AE, Jones BG, Ashmun RA et al. DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein. Mol Cell Biol 1994; 14: 3403-3413.
6. Yoshihara T, Inaba T, Shapiro LH, Kato JY, Look AT. E2A-HLFmediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF. Mol Cell Biol 1995; 15: 3247-3255.
7. Inukai T, Inaba T, Yoshihara T, Look AT. Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol Cell Biol 1997; 17: 1417-1424. (Pubitemid 27097370)
8. Inukai T, Inaba T, Ikushima S, Look AT. The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF. Mol Cell Biol 1998; 18: 6035-6043. (Pubitemid 28450554)
9. Seidel MG, Look AT. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 2001; 20: 5718-5725. (Pubitemid 32928109)
10. Smith KS, Rhee JW, Cleary ML. Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol 2002; 22: 7678-7687.
11. Smith KS, Chanda SK, Lingbeek M. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Molecular Cell 2003; 12: 393-400. (Pubitemid 37238926)
12. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298-2307. (Pubitemid 37128644)
13. Weinstein IB. Cancer. Addiction to oncogenesFthe Achilles heal of cancer. Science 2002; 297: 63-64. (Pubitemid 34743088)
14. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60. (Pubitemid 30041421)
15. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addictionFa rationale for molecular targeting in cancer therapy. Nat Clin Pract 2006; 3: 448-457. (Pubitemid 44203817)
16. Kurosawa H, Goi K, Inukai T, Inaba T, Chang KS, Shinjyo T et al. Two candidate downstream target genes for E2A-HLF. Blood 1999; 93: 321-332. (Pubitemid 29019419)
17. Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K et al. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999; 4: 343-352. (Pubitemid 29499787)
18. Dang J, Inukai T, Kurosawa H, Goi K, Inaba T, Lenny NT et al. The E2A-HLF oncoprotein activates Groucho-related genes and suppresses Runx1. Mol Cell Biol 2001; 21: 5935-5945. (Pubitemid 32737810)
19. Matsunaga T, Inaba T, Matsui H, Okuya M, Miyajima A, Inukai T et al. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood 2004; 103: 3185-3191. (Pubitemid 38451697)
20. Inaba T, Inukai T, Yoshihara T, Seyschab H, Ashmun RA, Canman CE et al. Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 1996; 382: 541-544. (Pubitemid 26260696)
21. Yeung J, Kempski H, Neat M, Bailey S, Smith O, Brady HJ. Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells. Haematologica 2006; 91: 422-424.
22. Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288-296. (Pubitemid 46158122)
23. Yeung J, O'Sullivan E, Hubank M, Brady HJM. E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells. Br J Haematol 2004; 125: 560-567. (Pubitemid 38747957)
24. Morrow M, Horton S, Kioussis D, Brady HJM, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004, 103, 3890-3896. (Pubitemid 38596310)
25. Dickins RA, HemannMT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289-1295. (Pubitemid 41568715)
26. Shojaei F, Trowbridge J, Gallacher L, Yuefei L, Goodale D, Karanu F et al. Hierarchial and ontogenic positions serve to define the molecular basis of human hematopoietic stem cell behavior. Dev Cell 2005; 8: 651-653.
27. Crable SC, Anderson KP. A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene. Blood 2003; 101: 4757-4764. (Pubitemid 36857732)
28. Nam CH, Rabbitts TH. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther 2006; 13: 15-25. (Pubitemid 41763479)
29. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249. (Pubitemid 38281277)
30. Ohyashiki K, Fujieda H, Miyauchi J, Ohyashiki JH, Tauchi T, Saito M et al. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t (17;19) chromosomal translocation the growth of which is inhibited by Interleukin-3. Leukaemia 1991; 5: 322-331.
31. Takahashi H, Goto H, Funabiki T, Fujii H, Yamazaki S, Fujioka K et al. Expression of two types of E2A-HLF fusion proteins in YCUB-2, a novel cell line established from B-lineage leukemia with t(17;19). Leukaemia 2001; 15: 995-997. (Pubitemid 32529906)
32. Greaves MF, Wiemels J. Origin of translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639-649.
33. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226-4237. (Pubitemid 27298175)
34. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
35. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602. (Pubitemid 13035496)
36. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987; 49: 465-475. (Pubitemid 18091823)
37. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
38. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Slany R. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628. (Pubitemid 38057914)
39. Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood 2010; 116: 962-970.